Hairy Cell Leukemia — Trials

Hairy Cell Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 21
Recruiting: 9
Ph III recruiting: 1
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (20)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	withdrawn	Phase 2	0	City of Hope Medical CenterOTHER	0	Dec 17, 2020	clinicaltrials
NCT02281279	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	withdrawn	Phase 1 / Phase 2	0	Mayo ClinicOTHER	0	Aug 11, 2016	clinicaltrials